Description: "Hear an overview of recent results and potential scenarios that may impact the future of the ACA market. Review recent reported industry level profitability before transitioning to a discussion of how current market dynamics may influence the future profitability of this segment. Results from microsimulation economic models will be presented to help illuminate market shifts. Issues that will be explored include how ICRA availability might influence individual decision making, as well as how a move to level funding is impacting the small group market. By attending this session, you will: Understand the recent average and variation of industry performance in the ACA market segment. Describe current policy and market forces that are expected to impact this segment. Explain the range of market scenarios that may result due to these forces."

Description: In this session, presenters will share the impacts of transition to IFRS 17 on equity and various KPIs across insurance companies (Life & P&C), as well as share some observations of what the IFRS 17 landscape looks like across different global regions. The session will conclude with lessons learned and expectations for emerging practices under IFRS 17 globally.

Description: Worried about the latest wildfires? Can't keep up with the latest geopolitical landscape? Wondering how close AI is to taking over? Join us as we discuss the results of the 18th edition of the Emerging Risk Survey. This is an annual survey which is jointly sponsored by the Casualty Actuarial Society and the Society of Actuaries Research Institute.

Description: This video from Ben Keslowitz explains the concept of reinsurance, which is a financial arrangement where insurance companies transfer portions of their risk portfolios to other parties, known as reinsurers. This helps insurers manage large or catastrophic claims and optimize their risk components. The video also covers different types of reinsurance, such as proportional liability reinsurance, non-proportional reinsurance, and quota share coinsurance, each serving different purposes in risk management. Additionally, it discusses the reasons insurers might choose to reinsure their business, including liability risk mitigation, investment risk transfer, and entering new markets.

Description: Are you ready to supercharge your career? Join us for an exciting webcast where industry experts will share how to leverage mentoring and networking for career success. Discover how these powerful tools can transform your professional journey, provide invaluable insights, and open doors to new opportunities. In this dynamic session, our speakers will share their personal stories and practical tips on building meaningful mentoring relationships. You’ll learn proven networking strategies to connect with influential professionals and accelerate your career growth. Don’t miss this chance to gain insider knowledge from industry leaders and receive actionable advice. Whether you’re just starting out or aiming to advance your career, this webcast will equip you with the tools and inspiration you need to succeed.

Description: In this webcast, we will speak with actuarial leaders who developed their personal brand over several years to better understand just how powerful having a personal brand can be in actuarial work.

Description: Mortality Model Selection and Combination in RAlternative approaches for selecting mortality models and forecasting mortality have been proposed. The usual practice is to base mortality forecasts on a single mortality model selected using in-sample goodness-of-fit measures. However, cross-validation and other alternative out-of-sample measures are increasingly being used in model selection, and model combination methods are becoming a common alternative to using a single mortality model. Such methods combine predictions from multiple mortality models to reduce model choice uncertainty and improve forecast accuracy. Explore techniques to select and combine mortality models using the freely available open source R package CoMoMo (https://github.com/kessysalvatory/CoMoMo), which extends the widely used R package StMoMo (https://CRAN.R-project.org/package=StMoMo). We will use data for the USA and other countries to discuss and demonstrate four different model combination approaches including simple model averaging, Bayesian model averaging, model confidence set, and stacked regression ensembles.

Description: "Living to 100 in the time of COVID-19: A Study of Late –Life Mortality Trajectories, Leonid A. Gavrilov, Ph.D., Natalia S. Gavrilova, Ph.D., Academic Research Centers, NORC at the University of Chicago Swedish Mortality Does Not Decelerate in Recent Cohorts, or Does it? – Roland Rau, Ph. D., Professor, University of Rostock & Max Planck Institute for Demographic Research, Rostock, Germany; Marcus Ebeling, Ph.D., Karin Modig, Ph.D., Associate Professor, Anders Ahlbom, Ph.D., Professor Emeritus, Karolinska Institute, Stockholm Sweden; Kai Kaufhold, Aktuar DAV, Ad Res Advanced Reinsurance Services GmbH, Cologne, Germany; Annika Ziegler, Lukas Stake, Hochschule Koblenz & Ad Res, Germany"

Description: Risk is opportunity! Equipped with skills to analyze risks, actuaries are no longer limited to applying these skills solely within traditional actuarial roles. Listen in as the presenters share their career experience in a non-traditional role and provide insights on how being an actuary can bring additional value to the profession.

Description: In this session, you will learn about key cost drivers in pharmacy trends, including but not limited to: New high-cost drugs, including gene therapies, that treat rare and/or expensive conditions such as spinal muscular atrophy (SMA), inherited retinal disease, hemophilia A and B, Duchenne muscular dystrophy (DMD), sickle cell anemia and cerebral adrenoleukodystrophy (CALD) Other cost drivers in the prescription drug category, including the emergence of GLP-1s, digital therapeutics, targeted immunomodulators, accelerated approval drugs and expanded indications The implications of the end of the COVID-19 Public Health Emergency (PHE) on the costs of COVID-19 vaccines, testing and treatment claims Downward influences on pharmacy costs, such as the availability of new generic drugs and biosimilars Emerging trends in pharmacy benefits manager (PBM) contracting, the initial portion of this discussion will be led by a pharmacist and former state pharmacy director.